130 related articles for article (PubMed ID: 31424016)
1. Relative potency of different generic brands of meropenem, colistin and fosfomycin: Implications for antimicrobial therapy and antimicrobial formulary.
Das P; Jana B; Dhar K; Goel G; Bhattacharya S; Chandy M
Indian J Med Microbiol; 2019; 37(1):95-98. PubMed ID: 31424016
[TBL] [Abstract][Full Text] [Related]
2. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
4. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
Albur MS; Noel A; Bowker K; MacGowan A
Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing
Wang J; He JT; Bai Y; Wang R; Cai Y
Biomed Res Int; 2018; 2018():5720417. PubMed ID: 29850537
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Evren E; Azap OK; Çolakoğlu Ş; Arslan H
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
[TBL] [Abstract][Full Text] [Related]
8. [Revival of selected well-tried antibiotics. Special features of the antiinfective agents penicillin G, fosfomycin, aztreonam and colistin].
Lipp HP
Med Monatsschr Pharm; 2012 Oct; 35(10):367-77. PubMed ID: 23094579
[TBL] [Abstract][Full Text] [Related]
9. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey.
Süzük Yıldız S; Kaşkatepe B; Şimşek H; Sarıgüzel FM
Acta Microbiol Immunol Hung; 2019 Mar; 66(1):103-112. PubMed ID: 30403361
[TBL] [Abstract][Full Text] [Related]
10. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
Sherry N; Howden B
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
[TBL] [Abstract][Full Text] [Related]
11. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong.
Ip M; Lai CK; Fung KSC; Wong KT; Zhu C; Van de Velde S; Tsang DN; Hawkey P
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2491-2494. PubMed ID: 28840351
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of effectiveness and safety of generic formulation of meropenem for treatment of infections at Siriraj Hospital.
Angkasekwinai N; Werarak P; Chaiyasoot K; Thamlikitkul V
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S217-24. PubMed ID: 21721450
[TBL] [Abstract][Full Text] [Related]
13. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.
Mohamed AF; Kristoffersson AN; Karvanen M; Nielsen EI; Cars O; Friberg LE
J Antimicrob Chemother; 2016 May; 71(5):1279-90. PubMed ID: 26850719
[TBL] [Abstract][Full Text] [Related]
14. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.
Agudelo M; Rodriguez CA; Pelaez CA; Vesga O
Antimicrob Agents Chemother; 2014; 58(2):1005-18. PubMed ID: 24277034
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
Berçot B; Poirel L; Dortet L; Nordmann P
J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
[TBL] [Abstract][Full Text] [Related]
16. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
Fan B; Guan J; Wang X; Cong Y
PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
[TBL] [Abstract][Full Text] [Related]
17. Fosfomycin: Resurgence of an old companion.
Sastry S; Doi Y
J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
[TBL] [Abstract][Full Text] [Related]
18. An
Sugathan S; Mandal J
J Med Microbiol; 2019 Dec; 68(12):1699-1706. PubMed ID: 31647407
[No Abstract] [Full Text] [Related]
19. Microbiological equivalence of serum bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving original meropenem (Meronem) and generic meropenem (Mero).
Thamlikitkul V; Tiengrim S; Chalermsri C; Chinsawangwatanakul P; Suddhichupaiboon S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S110-6. PubMed ID: 20364565
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergy and postantibiotic effect of colistin combinations with meropenem and vancomycin against Enterobacteriaceae with multiple carbapenem resistance mechanisms.
Bedenić B; Car H; Slačanac D; Sviben M; Čačić M; Lukić-Grlić A; Benčić A; Šijak D; Tripković M; Beader N
J Infect Chemother; 2018 Dec; 24(12):1016-1019. PubMed ID: 30006247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
